Augmentation of vascular permeability of VEGF is enhanced by KDR-binding proteins

Biochemical and Biophysical Research Communications

Volumn 355, Issue 3, 2007, Pages 693-699

  Yamazaki, Yasuo ^a   Nakano, Yuta ^a   Imamura, Takahisa ^b   Morita, Takashi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Age related macular degeneration (AMD); Snake venom; Tissue inhibitor of metalloproteinase 3 (TIMP 3); Vascular endothelial growth factor (VEGF); Vascular permeability; VEGF receptor 2 (KDR)

Indexed keywords

BINDING PROTEIN; SNAKE VENOM; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; VAMMIN; VASCULOTROPIN 165;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL GROWTH; CONTROLLED STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CAPILLARY PERMEABILITY; DRUG SYNERGISM; GUINEA PIGS; PHOSPHOLIPASES A; TISSUE INHIBITOR OF METALLOPROTEINASE-3; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIPER VENOMS;

EID: 33847310265     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.02.038     Document Type: Article

References (38)

1. Weis S.M., and Cheresh D.A. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437 (2005) 497-504
2. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237 (1999) 97-132
3. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., and Cheresh D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4 (1999) 915-924
4. Brown L.F., Dvorak A.M., and Dvorak H.F. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am. Rev. Respir. Dis. 140 (1989) 1104-1107
5. van Bruggen N., Thibodeaux H., Palmer J.T., Lee W.P., Fu L., Cairns B., Tumas D., Gerlai R., Williams S.P., van Lookeren Campagne M., and Ferrara N. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest. 104 (1999) 1613-1620
6. Weis S., Shintani S., Weber A., Kirchmair R., Wood M., Cravens A., McSharry H., Iwakura A., Yoon Y.S., Himes N., Burstein D., Doukas J., Soll R., Losordo D., and Cheresh D. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J. Clin. Invest. 113 (2004) 885-894
7. Garner A. Vascular diseases. In: Garner A., and Gordon K.K. (Eds). Pathobiology of Oular Disease (1994), Marcel Dekker, New York 1625-1710
8. Lopez P.F., Sippy B.D., Lambert H.M., Thach A.B., and Hinton D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 37 (1996) 855-868
9. Kvanta A., Algvere P.V., Berglin L., and Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 37 (1996) 1929-1934
10. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004) 581-611
11. Yamazaki Y., and Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol. Divers. 10 (2006) 515-527
12. Gille H., Kowalski J., Li B., LeCouter J., Moffat B., Zioncheck T.F., Pelletier N., and Ferrara N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 276 (2001) 3222-3230
13. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., and Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273 (1998) 30336-30343
14. Louzier V., Raffestin B., Leroux A., Branellec D., Caillaud J.M., Levame M., Eddahibi S., and Adnot S. Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 284 (2003) L926-L937
15. Park J.E., Chen H.H., Winer J., Houck K.A., and Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269 (1994) 25646-25654
16. Stacker S.A., Vitali A., Caesar C., Domagala T., Groenen L.C., Nice E., Achen M.G., and Wilks A.F. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J. Biol. Chem. 274 (1999) 34884-34892
17. Joukov V., Sorsa T., Kumar V., Jeltsch M., Claesson-Welsh L., Cao Y., Saksela O., Kalkkinen N., and Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16 (1997) 3898-3911
18. Olsson A.K., Dimberg A., Kreuger J., and Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 7 (2006) 359-371
19. Yamazaki Y., Takani K., Atoda H., and Morita T. Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2). J. Biol. Chem. 278 (2003) 51985-51988
20. Yamazaki Y., Matsunaga Y., Nakano Y., and Morita T. Identification of vascular endothelial growth factor receptor-binding protein in the venom of eastern cottonmouth. A new role of snake venom myotoxic Lys49-phospholipase A2. J. Biol. Chem. 280 (2005) 29989-29992
21. Qi J.H., Ebrahem Q., Moore N., Murphy G., Claesson-Welsh L., Bond M., Baker A., and Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 9 (2003) 407-415
22. Miles A.A., and Miles E.M. Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. J. Physiol. 118 (1952) 228-257
23. Murohara T., Horowitz J.R., Silver M., Tsurumi Y., Chen D., Sullivan A., and Isner J.M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97 (1998) 99-107
24. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C.O., Buerk D.G., Huang P.L., and Jain R.K. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. USA 98 (2001) 2604-2609
25. Yu W.H., Yu S., Meng Q., Brew K., and Woessner Jr. J.F. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J. Biol. Chem. 275 (2000) 31226-31232
26. Houck K.A., Leung D.W., Rowland A.M., Winer J., and Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267 (1992) 26031-26037
27. Veikkola T., Karkkainen M., Claesson-Welsh L., and Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60 (2000) 203-212
28. Wise L.M., Ueda N., Dryden N.H., Fleming S.B., Caesar C., Roufail S., Achen M.G., Stacker S.A., and Mercer A.A. Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens. J. Biol. Chem. 278 (2003) 38004-38014
29. Eliceiri B.P., Puente X.S., Hood J.D., Stupack D.G., Schlaepfer D.D., Huang X.Z., Sheppard D., and Cheresh D.A. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J. Cell Biol. 157 (2002) 149-160
30. Robinson S.D., Reynolds L.E., Wyder L., Hicklin D.J., and Hodivala-Dilke K.M. Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2108-2114
31. Jomary C., Neal M.J., Iwata K., and Jones S.E. Localization of tissue inhibitor of metalloproteinases-3 in neurodegenerative retinal disease. Neuroreport 8 (1997) 2169-2172
32. Kamei M., and Hollyfield J.G. TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 40 (1999) 2367-2375
33. Tymms M.J. Sorsby's fundus dystrophy: what does TIMP3 tell us about general mechanisms underlying macular degeneration?. Clin. Exp. Optom. 82 (1999) 124-129
34. Lee M.H., Knauper V., Becherer J.D., and Murphy G. Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. Biochem. Biophys Res. Commun. 280 (2001) 945-950
35. Langton K.P., McKie N., Curtis A., Goodship J.A., Bond P.M., Barker M.D., and Clarke M. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. J. Biol. Chem. 275 (2000) 27027-27031
36. Yeow K.M., Kishnani N.S., Hutton M., Hawkes S.P., Murphy G., and Edwards D.R. Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. Matrix Biol. 21 (2002) 75-88
37. Majid M.A., Smith V.A., Easty D.L., Baker A.H., and Newby A.C. Sorsby's fundus dystrophy mutant tissue inhibitors of metalloproteinase-3 induce apoptosis of retinal pigment epithelial and MCF-7 cells. FEBS Lett. 529 (2002) 281-285
38. Fariss R.N., Apte S.S., Luthert P.J., Bird A.C., and Milam A.H. Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa. Br. J. Ophthalmol. 82 (1998) 1329-1334